Celgene Announces Phase II Study Evaluates Clinical Benefit of Combining REVLIMID with rituximab to Enhance Anti-Cancer Activity in Mantle Cell Lymphoma

Celgene International Sàrl CELG announced that clinical data from a Phase I/II study evaluating the combination of REVLIMID plus rituximab in relapsed/refractory mantle cell lymphoma, conducted by investigators at the MD Anderson Cancer Center in Houston, TX, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland. Patients with MCL who had received one to four prior therapies received REVLIMID daily on days one to 21 of each 28-day cycle, and rituximab weekly for four doses during cycle one. The maximum tolerated dose in the phase I portion was 20 mg of REVLIMID daily, and 375 mg/m2 of rituximab in accordance with the study schedule.